4/24
07:10 am
fwbi
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients [Yahoo! Finance]
Medium
Report
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients [Yahoo! Finance]
4/24
07:00 am
fwbi
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
Medium
Report
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
4/17
07:00 am
fwbi
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
Medium
Report
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
4/15
07:00 am
fwbi
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
Medium
Report
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
4/5
11:59 am
fwbi
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
Low
Report
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
3/27
01:29 pm
fwbi
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
First Wave BioPharma (FWBI) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]
3/25
08:07 am
fwbi
First Wave BioPharma, Inc. (NASDAQ: FWBI) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
First Wave BioPharma, Inc. (NASDAQ: FWBI) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/18
03:01 pm
fwbi
First Wave BioPharma, Inc. (NASDAQ: FWBI) had its price target lowered by analysts at Roth Mkm from $40.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
First Wave BioPharma, Inc. (NASDAQ: FWBI) had its price target lowered by analysts at Roth Mkm from $40.00 to $36.00. They now have a "buy" rating on the stock.
3/18
07:09 am
fwbi
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference [Yahoo! Finance]
Medium
Report
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference [Yahoo! Finance]
3/18
07:00 am
fwbi
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Low
Report
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
3/14
06:11 am
fwbi
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline [Yahoo! Finance]
High
Report
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline [Yahoo! Finance]
3/14
06:00 am
fwbi
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
High
Report
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
3/5
07:11 am
fwbi
First Wave BioPharma to Participate In ‘Fireside Chat' at the 36th Annual Roth Conference [Yahoo! Finance]
Medium
Report
First Wave BioPharma to Participate In ‘Fireside Chat' at the 36th Annual Roth Conference [Yahoo! Finance]
3/5
07:00 am
fwbi
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
Low
Report
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
3/4
08:16 am
fwbi
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering [Yahoo! Finance]
Low
Report
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering [Yahoo! Finance]
3/4
08:00 am
fwbi
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
Medium
Report
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
2/13
07:00 am
fwbi
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
Medium
Report
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024